Biblio
2023
Rodriguez-Zabala M, Ramakrishnan R, Reinbach K, Ghosh S, Oburoglu L, Falqués-Costa A, Bellamkonda K, Ehinger M, Peña-Martínez P, Puente-Moncada N, et al. Combined GLUT1 and OXPHOS inhibition eliminates acute myeloid leukemia cells by restraining their metabolic plasticity. Blood Adv. 2023.
2022
Modvig S, Wernersson R, Øbro NFriesgaard, Olsen LRønn, Christensen C, Rosthøj S, Degn M, Jürgensen GWullf, Madsen HO, Albertsen BKlug, et al. High CD34 surface expression in BCP-ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion. Mol Oncol. 2022.
2021
Stenzinger A, Edsjö A, Ploeger C, Friedman M, Fröhling S, Wirta V, Seufferlein T, Botling J, Duyster J, Akhras M, et al. Trailblazing Precision Medicine in Europe: a joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany. Semin Cancer Biol. 2021.
2020
Yang M, Safavi S, Woodward EL, Duployez N, Olsson-Arvidsson L, Ungerbäck J, Sigvardsson M, Zaliova M, Zuna J, Fioretos T, et al. 13q12.2 deletions in acute lymphoblastic leukemia lead to upregulation of FLT3 through enhancer hijacking. Blood. 2020.